Dr. Ezra Cohen on Siltuximab Combinations in Head and Neck Squamous Cell Carcinoma
The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel.
Ezra Cohen, MD, professor of medicine, UC San Diego Moores Cancer Center, discusses a recent study looking at integrating siltuximab into two different chemotherapy radiation platforms. The two platforms involved in the study were the FHX regimen and a cisplatin radiation approach with accelerated radiation. Siltuximab was also used in the study as induction chemotherapy alongside carboplatin and paclitaxel. Cohen says patients were initially given the triplet, and then randomized to either the FHX regimen and a cisplatin radiation approach.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
